CMS
58
-2
EW
32
3
DRI
56
2
EXR
59
4
EFX
41
-2
DOV
73
4
GPC
40
2
ROK
67
5
INTC
49
16
NWS
79
-4
T
48
3
AVGO
35
-2
UPS
50
9
BMY
61
-3
WFC
80
-2
NOC
40
-10
EMC
53
-3
NKE
33
2
ETR
68
-3
SE
60
-5
CMS
58
-2
EW
32
3
DRI
56
2
EXR
59
4
EFX
41
-2
DOV
73
4
GPC
40
2
ROK
67
5
INTC
49
16
NWS
79
-4
T
48
3
AVGO
35
-2
UPS
50
9
BMY
61
-3
WFC
80
-2
NOC
40
-10
EMC
53
-3
NKE
33
2
ETR
68
-3
SE
60
-5
Financhill
Back

Intellia Therapeutics 10K Form

Sell
29

NTLA
Intellia Therapeutics

Last Price:
15.12
Seasonality Move:
12.78%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NTLA News And Ratings

See the #1 stock for the next 7 days that we like better than NTLA

NTLA Financial Statistics

Sales & Book Value

Annual Sales: $36.28M
Cash Flow: $-86.12M
Price / Cash Flow: 0
Annual Sales: $9.46
Price / Book: 1.76

Profitability

EPS (TTM): -5.44000
Net Income (TTM): $-522.28M
Gross Margin: --
Return on Equity: -51.64%
Return on Assets: -42.33%

Intellia Therapeutics Earnings Forecast

Key Intellia Therapeutics Financial Ratios

  • The Research & Development expenses have been 1,199.36% of Revenue.
  • The Net Earning history of NTLA is -1,326.51% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 1 years.

Intellia Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: NTLA
CUSIP: 45826J
Website: intelliatx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.73
Quick Ratio: 6.31

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NTLA Technical Analysis vs Fundamental Analysis

Sell
29
Intellia Therapeutics (NTLA) is a Sell

Is Intellia Therapeutics a Buy or a Sell?